Topics covered in this update include: payers’ approaches to the reimbursement of Ocrevus (ocrelizumab; Roche/Biogen) for relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS); the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways by which Biogen could retain market share of Tecfidera.
How do payers react to the recent approval of ocrelizumab?
How is ocrelizumab likely to be covered in the US?
How do US payers feel about ocrelizumab’s competitive pricing? Are there any apprehensions?
How do payers react to the delay in launch of generic Copaxone 40mg/ml?
According to payers, what can Teva do to retain its market share of branded Copaxone 40mg/ml?
According to payers, what can Biogen do to retain market share of Tecfidera?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.